Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | PPM1B | O75688 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17730047 | 1.00 | SHBG (0.48) | SHBGL3MBTL1CYP2D6ALDH1A1NPSR1 | |
| SCHEMBL29525633 | 1.00 | SHBG (0.48) | SHBGL3MBTL1CYP2D6ALDH1A1NPSR1 | |
| SCHEMBL27350614 | 0.85 | L3MBTL1 (0.40) | SHBGL3MBTL1CYP2D6ALDH1A1NPSR1 | |
| SCHEMBL13573000 | 0.85 | CYP2D6 (0.46) | SHBGL3MBTL1CYP2D6ALDH1A1NPSR1 | |
| SCHEMBL31547066 | 0.85 | CYP2D6 (0.46) | SHBGL3MBTL1CYP2D6ALDH1A1NPSR1 | |
| SCHEMBL4087213 | 0.83 | ALDH1A1 (0.48) | SHBGL3MBTL1CYP2D6ALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL27351255 | 0.81 | ALDH1A1 (0.47) | SHBGL3MBTL1CYP2D6ALDH1A1NPSR1 | |
| SCHEMBL17729118 | 0.80 | CPN1 (0.47) | L3MBTL1CYP2D6ALDH1A1NPSR1 | |
| SCHEMBL1188235 | 0.79 | SHBG (0.45) | SHBGL3MBTL1CYP2D6ALDH1A1NPSR1 | |
| SCHEMBL1188237 | 0.79 | SHBG (0.45) | SHBGL3MBTL1CYP2D6ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337970-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210290613-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-23 | — | — | US | disclosed |
| EP-3854394-A1 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-107427499-B | Immunomodulator | 弗莱塞斯生物科学公司 | 2021-04-16 | — | — | CN | disclosed |
| EP-3215142-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3215153-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10544099-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190119216-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-10206893-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190002472-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-10106546-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180282281-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2018-10-04 | — | — | US | disclosed |
| EP-3215142-A2 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170197973-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9643972-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9598422-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160137652-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2016073774-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | SHBG 769/4885L3MBTL1 3766/4885CYP2D6 836/4885 |
| US-10106546-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | SHBG 769/4885L3MBTL1 3766/4885CYP2D6 836/4885 |
| US-10206893-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | SHBG 769/4885L3MBTL1 3766/4885CYP2D6 836/4885 |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | SHBG 769/4885L3MBTL1 3766/4885CYP2D6 836/4885 |
| US-20180282281-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | SHBG 769/4885L3MBTL1 3766/4885CYP2D6 836/4885 |
| US-20160137652-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | SHBG 769/4885L3MBTL1 3766/4885CYP2D6 836/4885 |
| US-10544099-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | SHBG 2614/4885L3MBTL1 3862/4885CYP2D6 699/4885 |
| US-20190002472-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | SHBG 769/4885L3MBTL1 3766/4885CYP2D6 836/4885 |
| US-11337970-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | SHBG 2614/4885L3MBTL1 3862/4885CYP2D6 699/4885 |
| US-20170197973-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | SHBG 769/4885L3MBTL1 3766/4885CYP2D6 836/4885 |
| US-20190119216-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | SHBG 2614/4885L3MBTL1 3862/4885CYP2D6 699/4885 |
| US-20210290613-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | SHBG 2614/4885L3MBTL1 3862/4885CYP2D6 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.